VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

09 май 2024 04:00:01 Источник Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

01 май 2024 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

24 апр 2024 23:00:00 Источник Nasdaq GlobeNewswire

Andrew Fisher Joins Verona Pharma as General Counsel

03 мар 2024 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

28 фев 2024 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update

14 фев 2024 23:00:00 Источник Nasdaq GlobeNewswire

Michael Austwick Joins Verona Pharma as Non-Executive Director

31 янв 2024 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference

02 янв 2024 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

01 янв 2024 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma’s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award

16 ноя 2023 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces November 2023 Investor Conference Participation

07 ноя 2023 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update

02 ноя 2023 00:04:23 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update

18 окт 2023 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023

05 окт 2023 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023

02 окт 2023 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD

10 сен 2023 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

05 сен 2023 23:00:00 Источник Nasdaq GlobeNewswire

Christina Ackermann Joins Verona Pharma as Non-Executive Director

30 авг 2023 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update

02 авг 2023 23:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present at 43rd Annual Canaccord Growth Conference

25 июл 2023 23:00:00 Источник Nasdaq GlobeNewswire